Clinical trials: Metastatic Colorectal Cancer (MCRC)
Metastatic Colorectal Cancer
Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients
Currently, the approved third-line treatments for metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine/tipiracil(TAS-102).
- Trial name
- NCT06403709
- Testing
- Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metastatic Colorectal Cancer (mCRC)
Randomized Controlled Trial of the Effects of Combined Resistance and AerobiC Exercise on Health-related Quality of Life in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer (REACH)
The primary objective of this trial is to compare the effects of 18 weeks structured exercise training versus on control on healt-related quality of life in patients with mCRC undergoing first-line chemotherapy.
- Trial name
- REACH (NCT06938971)
- Testing
- Exercise training
- Where
- 4 sites in Denmark
- Volunteers
- 150 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Metastatic Colorectal Cancer
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer
This is a Phase II, multicenter, single-arm trial designed to evaluate the efficacy and safety of nivolumab (NIVO), ipilimumab (IPI) and temozolomide (TMZ) combination in 27 patients with MSS, MGMT-silenced mCRC with initial…
- Trial name
- MAYA (NCT03832621)
- Testing
- Temozolomide, Nivolumab, Ipilimumab
- Where
- Italy
- Volunteers
- 135 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Colorectal Cancer Metastatic
Radioembolization in Elderly/ Fragile Patients With mCRC
Radioembolization (RE) is a minimally invasive treatment with administration of radioactive microspheres into the hepatic artery via a microcatheter.
- Trial name
- CAIRO7 (NCT05092880)
- Testing
- radioembolization, Standard of care first-line systemic therapy
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- UMC Utrecht
Metastatic Colorectal Cancer
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
This Study is in two parts, the first part is to make sure that combining a potential new treatment, cediranib (AZD2171), with a standard treatment (FOLFOX) for metastatic colorectal cancer is safe.
- Trial name
- NCT00494221
- Testing
- AZD2171, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- 2 sites in Japan
- Volunteers
- 172 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
The purpose of this study is to determine whether SCT200 is safe and tolerant in the treatment of metastatic colorectal cancer
- Trial name
- NCT02211443
- Testing
- Recombinant full human Anti-EGFR Monoclonal Antibody
- Volunteers
- 21 people
- Sponsor
- Sinocelltech Ltd.
Metastatic Colorectal Cancer (CRC)
A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC)
This study is conducted sequentially in 3 parts. The primary objective for Part 1 is to determine the maximum tolerated dose of DES-1357 in participants with confirmed dMMR/MSI-H colorectal cancer (CRC).
- Trial name
- NCT07807800
- Testing
- DES-1357
- Volunteers
- 88 people
- Sponsor
- D. E. Shaw Research, LLC
Metastatic Colorectal Cancer, BRAF V600E Mutation
Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer
This study prospectively investigates the molecular mechanisms of primary and acquired resistance to standard-of-care BRAF V600E-directed therapy in patients with metastatic colorectal cancer and aims to pre-clinically develop…
- Trial name
- PARTACER (NCT07617610)
- Testing
- Longitudinal translational sampling
- Where
- 13 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- Swiss Cancer Institute
Metastatic Colorectal Cancer (CRC)
Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC
This study aims to evaluate the effectiveness and safety of combining fruquintinib (an oral anti-angiogenesis drug) with cetuximab-beta (an anti-EGFR antibody) in patients with RAS wild-type metastatic colorectal cancer who have…
- Trial name
- NCT07724223
- Testing
- Fruquintinib plus Cetuximab-beta
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Neoplasms Malignant
Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
This was a single-arm, prospective study to investigate the safety of cetuximab in combination with trifluridin tipiracil (TAS-102) in the third-line treatment of Chinese patients with RAS wild-type mCRC.
- Trial name
- NCT05155124
- Testing
- Cetuximab + trifluridin tipiracil
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Breast Cancer, Colorectal Cancer
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
This pilot, non-interventional, observational, Web-based, prospective cohort study is designed to collect self-reported safety and effectiveness and genetic data from subjects with locally recurrent breast cancer (BC) or…
- Conditions
- Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma
- Trial name
- NCT01598597
- Where
- 50 sites in United States
- Volunteers
- 276 people
- Sponsor
- Genentech, Inc.
Metastatic Colorectal Cancer
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
This is a Phase 2, multicenter, multiple-arm, open-label study to evaluate the efficacy, safety, and tolerability of EZN-2208. EZN-2208 will be administered as a single agent in patients with K-RAS mutations in the tumors.
- Trial name
- NCT00931840
- Testing
- EZN-2208, Cetuximab and Irinotecan
- Where
- 60 sites in United States, Canada and 3 more
- Volunteers
- 220 people
- Sponsor
- Enzon Pharmaceuticals, Inc.
Metastatic Colorectal Cancer
The Gene Profiles of Primary and Heterogeneous Metastases of Colorectal Cancer
The incidence and mortality of colorectal cancer in China's cancer disease spectrum is on the rise, and it is a common malignant tumor that harms the health of Chinese residents.In patients with synchronous metastatic colorectal…
- Trial name
- NCT04230018
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer Metastatic
FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema
The purpose of this interventional study is to assess the progression free survival (one year) of patients with treatment of FOLFIRI and cetuximab, combined with an optional dermal prophylaxis. Further Objectives: 1.
- Trial name
- DERMATUX (NCT01315990)
- Testing
- FOLFIRI + Cetuximab
- Where
- Germany
- Volunteers
- 165 people
- Sponsor
- Dr. Carl Schimanski
Metastatic Colorectal Cancer
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
The study is designed as phase III, randomized, two armed, parallel, double blind (patient and assessor blinded), active controlled, and equivalency clinical trial with primary endpoint of Progression-Free Survival of Cetuximab®…
- Trial name
- NCT03391934
- Testing
- Cetuximab + FOLFIRI
- Where
- Iran
- Volunteers
- 234 people
- Sponsor
- Cinnagen
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
This phase Ib/II trial studies the side effects and best dose of SX-682 that can be given alone and in combination with nivolumab in treating patients with RAS-Mutated, microsatellite stable (MSS) colorectal cancer that has…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8
- Trial name
- NCT04599140
- Testing
- CXCR1/2 Inhibitor SX-682, Nivolumab
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Colorectal Cancer
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in…
- Trial name
- NCT04073615
- Testing
- Rivoceranib, Trifluridine/Tipiracil
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Elevar Therapeutics
Metastatic Colorectal Cancer
MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)
The research trial is testing the experimental treatment pimasertib (MSC1936369B) in combination with FOLFIRI, as second-line treatment in metastatic K Ras mutated colorectal cancer subjects.
- Trial name
- NCT01085331
- Testing
- Pimasertib, FOLFIRI
- Where
- 3 sites in Belgium, Italy and 1 more
- Volunteers
- 16 people
- Sponsor
- EMD Serono
Colorectal Neoplasms Malignant
Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC
This is a multicenter, randomized, controlled, phase II study to evaluate the efficacy and safety of tislelizumab combined with cetuximab and irinotecan（group A） compared to third-line regimens selected by researchers（group B） in…
- Trial name
- NCT05278351
- Testing
- Tislelizumab Combined With Cetuximab and Irinotecan, Third-line regimens
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Shanghai Zhongshan Hospital
Metastatic Colorectal Cancer
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to see if alternating chemotherapy with erlotinib increases tumor shrinkage in people with metastatic colorectal cancer.
- Trial name
- NCT00642746
- Testing
- Erlotinib, Fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- OHSU Knight Cancer Institute